Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unraveling Molecular Recognition of Glycan Ligands by Siglec-9 via NMR Spectroscopy and Molecular Dynamics Modeling

  • Atxabal, Unai|||0000-0002-0546-8521
  • Nycholat, Corwin
  • Pröpster, Johannes M.
  • Fernández, Andrea
  • Oyenarte, Iker
  • Lenza, Maria Pia
  • Franconetti, Antonio|||0000-0002-7972-8795
  • Soares, Cátia O.
  • Coelho, Helena|||0000-0003-1992-8557
  • Marcelo, Filipa
  • Schubert, Mario|||0000-0003-0278-4091
  • Paulson, James C.|||0000-0003-4589-5322
  • Jiménez Barbero, Jesús|||0000-0001-5421-8513
  • Ereño-Orbea, June|||0000-0002-5076-2105
Human sialic-acid-binding immunoglobulin-like lectin-9 (Siglec-9) is a glycoimmune checkpoint receptor expressed on several immune cells. Binding of Siglec-9 to sialic acid containing glycans (sialoglycans) is well documented to modulate its functions as an inhibitory receptor. Here, we first assigned the amino acid backbone of the Siglec-9 V-set domain (Siglec-9d1), using well-established triple resonance three-dimensional nuclear magnetic resonance (NMR) methods. Then, we combined solution NMR and molecular dynamic simulation methods to decipher the molecular details of the interaction of Siglec-9 with the natural ligands α2,3 and α2,6 sialyl lactosamines (SLN), sialyl Lewis X (sLeX), and 6-O sulfated sLeX and with two synthetically modified sialoglycans that bind with high affinity. As expected, Neu5Ac is accommodated between the F and G β-strands at the canonical sialic acid binding site. Addition of a heteroaromatic scaffold 9N-5-(2-methylthiazol-4-yl)thiophene sulfonamide (MTTS) at the C9 position of Neu5Ac generates new interactions with the hydrophobic residues located at the G-G' loop and the N-terminal region of Siglec-9. Similarly, the addition of the aromatic substituent (5-N-(1-benzhydryl-1H-1,2,3-triazol-4-yl)methyl (BTC)) at the C5 position of Neu5Ac stabilizes the conformation of the long and flexible B'-C loop present in Siglec-9. These results expose the underlying mechanism responsible for the enhanced affinity and specificity for Siglec-9 for these two modified sialoglycans and sheds light on the rational design of the next generation of modified sialoglycans targeting Siglec-9.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Exploring multivalent carbohydrate–protein interactions by NMR

  • Quintana, Jon I.
  • Atxabal Arrasate, Unai
  • Unione, Luca
  • Ardá, Ana
  • Jiménez Barbero, Jesús
Nuclear Magnetic Resonance (NMR) has been widely employed to assess diverse features of glycan–protein molecular recognition events. Different types of qualitative and quantitative information at different degrees of resolution and complexity can be extracted from the proper application of the available NMR-techniques. In fact, affinity, structural, kinetic, conformational, and dynamic characteristics of the binding process are available. Nevertheless, except in particular cases, the affinity of lectin-sugar interactions is weak, mostly at the low mM range. This feature is overcome in biological processes by using multivalency, thus augmenting the strength of the binding. However, the application of NMR methods to monitor multivalent lectin–glycan interactions is intrinsically challenging. It is well known that when large macromolecular complexes are formed, the NMR signals disappear from the NMR spectrum, due to the existence of fast transverse relaxation, related to the large size and exchange features. Indeed, at the heart of the molecular recognition event, the associated free-bound chemical exchange process for both partners takes place in a particular timescale. Thus, these factors have to be considered and overcome. In this review article, we have distinguished, in a subjective manner, the existence of multivalent presentations in the glycan or in the lectin. From the glycan perspective, we have also considered whether multiple epitopes of a given ligand are presented in the same linear chain of a saccharide (i.e., poly-LacNAc oligosaccharides) or decorating different arms of a multiantennae scaffold, either natural (as in multiantennae N-glycans) or synthetic (of dendrimer or polymer nature). From the lectin perspective, the presence of an individual binding site at every monomer of a multimeric lectin may also have key consequences for the binding event at different levels of complexity., We thank generous funding by the European Research Council (RECGLYCANMR, Advanced Grant No. 788143), the Agencia Estatal de Investigación (Spain) for grant PDI2021-1237810B-C21, and CIBERES, an initiative of Instituto de Salud Carlos III (ISCIII), Madrid, Spain. We also thank Marie-Skłodowska-Curie actions (TN BactiVax, under grant agreement No. 860325).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants

  • Romerio, Alessio
  • Gotri, Nicole
  • Franco, Ana Rita
  • Artusa, Valentina
  • Shaik, Mohammed Monsoor
  • Pasco, Samuel T.
  • Atxabal Arrasate, Unai
  • Matamoros Recio, Alejandra
  • Mínguez Toral, Marina
  • Zalamea, Juan Diego
  • Franconetti García, Antonio
  • Abrescia, Nicola G. A.
  • Jiménez Barbero, Jesús
  • Anguita Castillo, Juan de Dios
  • Martín Santamaría, Sonsoles
  • Peri, Francesco
We disclose here a panel of small-molecule TLR4 agonists (the FP20 series) whose structure is derived from previously developed TLR4 ligands (FP18 series). The new molecules have increased chemical stability and a shorter, more efficient, and scalable synthesis. The FP20 series showed selective activity as TLR4 agonists with a potency similar to FP18. Interestingly, despite the chemical similarity with the FP18 series, FP20 showed a different mechanism of action and immunofluorescence microscopy showed no NF-κB nor p-IRF-3 nuclear translocation but rather MAPK and NLRP3-dependent inflammasome activation. The computational studies related a 3D shape of FP20 series with agonist binding properties inside the MD-2 pocket. FP20 displayed a CMC value lower than 5 μM in water, and small unilamellar vesicle (SUV) formation was observed in the biological activity concentration range. FP20 showed no toxicity in mouse vaccination experiments with OVA antigen and induced IgG production, thus indicating a promising adjuvant, The authors acknowledge the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie, project BactiVax (www.bactivax.eu) grant agreement no. 860325; the consortium CINMPIS; the project of excellence CHRONOS, CHRonical multifactorial disorders explored by NOvel integrated Strategies of the Department of Biotechnology and Biosciences; the Agencia Estatal de Investigacion (Spain) for project PID2021-126130OB-I00 (N.G.A.A.), PID2020-113588RB-I00 (S.M.-S.), PRE2018-086249 (A.M.-R), PRE2021-097247 (M.M.-T.); and project FEDER MINECO, the EM-platform at the CIC bioGUNE for support in cryo-EM imaging. J.J.-B. also thanks funding by CIBERES, an initiative of Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Perkin-Elmer Italia is also acknowledged for providing the cell imaging reagents.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Structures of the Inhibitory Receptor Siglec-8 in Complex with a High-Affinity Sialoside Analogue and a Therapeutic Antibody

  • Lenza, Maria Pia
  • Atxabal Arrasate, Unai
  • Nycholat, Corwin
  • Oyenarte Santamaría, Iker
  • Franconetti García, Antonio
  • Quintana García, Jon Imanol
  • Delgado, Sandra
  • Núñez Franco, Reyes
  • Garnica Marroquín, Carmen Teresa
  • Coelho, Helena
  • Unione, Luca
  • Jiménez Oses, Gonzalo
  • Marcelo, Filipa
  • Schubert, Mario
  • Paulson, James C.
  • Jiménez Barbero, Jesús
  • Ereño Orbea, June
Human sialic acid binding immunoglobulin-like lectin-8 (Siglec-8) is an inhibitory receptor that triggers eosinophil apoptosis and can inhibit mast cell degranulation when engaged by specific monoclonal antibodies (mAbs) or sialylated ligands. Thus, Siglec-8 has emerged as a critical negative regulator of inflammatory responses in diverse diseases, such as allergic airway inflammation. Herein, we have deciphered the molecular recognition features of the interaction of Siglec-8 with the mAb lirentelimab (2C4, under clinical development) and with a sialoside mimetic with the potential to suppress mast cell degranulation. The three-dimensional structure of Siglec-8 and the fragment antigen binding (Fab) portion of the anti-Siglec-8 mAb 2C4, solved by X-ray crystallography, reveal that 2C4 binds close to the carbohydrate recognition domain (V-type Ig domain) on Siglec-8. We have also deduced the binding mode of a high-affinity analogue of its sialic acid ligand (9-N-napthylsufonimide-Neu5Ac, NSANeuAc) using a combination of NMR spectroscopy and X-ray crystallography. Our results show that the sialoside ring of NSANeuAc binds to the canonical sialyl binding pocket of the Siglec receptor family and that the high affinity arises from the accommodation of the NSA aromatic group in a nearby hydrophobic patch formed by the N-terminal tail and the unique G–G′ loop. The results reveal the basis for the observed high affinity of this ligand and provide clues for the rational design of the next generation of Siglec-8 inhibitors. Additionally, the specific interactions between Siglec-8 and the N-linked glycans present on the high-affinity receptor FcεRIα have also been explored by NMR., This work was supported by operating grant PID2019-107770RA-I00 (J.E.-O.) from the Agencia Estatal Investigación of Spain and by the European Research Council (ERC-2017-AdG, 788143-RECGLYCANMR to J.J.-B.). We also thank the Marie-Skłodowska-Curie actions (ITN Glytunes grant agreement no. 956758 to J.E.-O and ITN BactiVax under grant agreement no. 860325 to U.A.). Additional funding was provided by CIBER, an initiative of Instituto de Salud Carlos III (ISCIII), Madrid, Spain. We also thank the Ikerbasque Basque Foundation of Science and the Spanish Ministry of Economy, Industry and Competitiveness (for the postdoctoral contract Juan de la Cierva Incorporación to J.E-O). X-ray diffraction experiments described in this paper were performed using the XALOC synchrotron beamline at ALBA (Spain) and PXIII in Swiss Light Source (Switzerland).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthetic glycolipids as molecular vaccine adjuvants: mechanism of action in human cells and in vivo activity

  • Facchini, Fabio A.
  • Minotti, Alberto
  • Luraghi, Andrea
  • Romerio, Alessio
  • Gotri, Nicole
  • Matamoros-Recio, Alejandra
  • Iannucci, Andrea
  • Palmer, Charys
  • Wang, Guanbo
  • Ingram, Rebecca
  • Martín-Santamaría, Sonsoles
  • Pirianov, Grisha
  • De Andrea, Marco
  • Valvano, Miguel A.
  • Peri, Francesco
12 p.-7 fig.-1 schem.-1 graph. abst., Modern adjuvants for vaccine formulations are immunostimulating agents whose action is based on the activation of pattern recognition receptors (PRRs) by well-defined ligands to boost innate and adaptive immune responses. Monophosphoryl lipid A (MPLA), a detoxified analogue of lipid A, is a clinically approved adjuvant that stimulates toll-like receptor 4 (TLR4). The synthesis of MPLA poses manufacturing and quality assessment challenges. Bridging this gap, we report here the development and preclinical testing of chemically simplified TLR4 agonists that could sustainably be produced in high purity and on a large scale. Underpinned by computational and biological experiments, we show that synthetic monosaccharide-based molecules (FP compounds) bind to the TLR4/MD-2 dimer with submicromolar affinities stabilizing the active receptor conformation. This results in the activation of MyD88- and TRIF-dependent TLR4 signaling and the NLRP3 inflammasome. FP compounds lack in vivo toxicity and exhibit adjuvant activity by stimulating antibody responses with a potency comparable to MPLA., The support from European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 860325 (www.BactiVax.eu), Italian Ministry grant PRIN 2017, no. 2017E44A9P (BacHounds:Supramolecular nanostructures for bacteria detection), and the Spanish Ministry for Science and Innovation (grants CTQ2017-88353-R and PRE2018-086249) is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New glucosamine-based TLR4 agonists: design, synthesis, mechanism of action, and in vivo activity as vaccine adjuvants

  • Romerio, Alessio
  • Gotri, Nicole
  • Franco, Ana Rita
  • Artusa, Valentina
  • Shaik, Mohammed Monsoor
  • Pasco, Samuel T.
  • Atxabal, Unai
  • Matamoros-Recio, Alejandra
  • Mínguez-Toral, Marina
  • Zalamea, Juan Diego
  • Franconetti, Antonio
  • Abrescia, Nicola G. A.
  • Jiménez-Barbero, Jesús
  • Anguita, Juan
  • Martín-Santamaría, Sonsoles
  • Peri, Francesco
20 p.-15 fig.-1 graph. abst., We disclose here a panel of small-molecule TLR4 agonists (the FP20 series) whose structure is derived from previously developed TLR4 ligands (FP18 series). The new molecules have increased chemical stability and a shorter, more efficient, and scalable synthesis. The FP20 series showed selective activity as TLR4 agonists with a potency similar to FP18. Interestingly, despite the chemical similarity with the FP18 series, FP20 showed a different mechanism of action and immunofluorescence microscopy showed no NF-κB nor p-IRF-3 nuclear translocation but rather MAPK and NLRP3-dependent inflammasome activation. The computational studies related a 3D shape of FP20 series with agonist binding properties inside the MD-2 pocket. FP20 displayed a CMC value lower than 5 μM in water, and small unilamellar vesicle (SUV) formation was observed in the biological activity concentration range. FP20 showed no toxicity in mouse vaccination experiments with OVA antigen and induced IgG production, thus indicating a promising adjuvant activity., The authors acknowledge the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie, project BactiVax (www.bactivax.eu) grant agreement no. 860325; the consortium CINMPIS; the project of excellence CHRONOS, CHRonical multifactorial disorders explored by NOvel integrated Strategies of the Department of Biotechnology and Biosciences; the Agencia Estatal de Investigacion (Spain) for project PID2021-126130OB-I00 (N.G.A.A.), PID2020-113588RB-I00 (S.M.-S.), PRE2018-086249 (A.M.-R), PRE2021-097247 (M.M.-T.); and project FEDER MINECO, the EM-platform at the CIC bioGUNE for support in cryo-EM imaging. J.J.-B. also thanks funding by CIBERES, an initiative of Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Perkin-Elmer Italia is also acknowledged for providing the cell imaging reagents., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The microbiota metabolite, phloroglucinol, confers long-term protection against inflammation

  • Castelo, Janire
  • Araujo-Aris, Sarai
  • Barriales, Diego
  • Tanner Pasco, Samuel
  • Seoane, Iratxe
  • Peña-Cearra, Ainize
  • Palacios, Ainhoa
  • Simó, Carolina
  • García-Cañas, Virginia
  • Khamwong, Muthita
  • Martín-Ruiz, Itziar
  • Gonzalez-Lopez, Monika
  • Bárcena, Laura
  • Martín Rodríguez, José Ezequiel
  • Lavín, José Luís
  • Gutiez, Naiara
  • Marcos-Fernández, Raquel
  • Atondo, Estíbaliz
  • Cobela, Arantza
  • Plaza-Vinuesa, Laura
  • Plata, Adrián
  • Santos-Fernandez, Eneko
  • Fernandez-Tejada, Alberto
  • Villarán, Mari Carmen
  • Mancheño, Jose M.
  • Maria Flores, Juana
  • María Aransay, Ana
  • Pellón, Aize
  • De Las Rivas, Blanca
  • Muñoz, Rosario
  • Margolles Barros, Abelardo
  • Ruas-Madiedo, Patricia
  • Victoria Selma, Maria
  • Gomez de Agüero, Mercedes
  • Abecia, Leticia
  • Anguita, Juan
  • Rodríguez, Héctor
Phloroglucinol is a key byproduct of gut microbial metabolism that has been widely used as a treatment for irritable bowel syndrome. Here, we demonstrate that phloroglucinol tempers macrophage responses to pro-inflammatory pathogens and stimuli. In vivo, phloroglucinol administration decreases gut and extraintestinal inflammation in murine models of inflammatory bowel disease and systemic infection. The metabolite induces modest modifications in the microbiota. However, the presence of an active microbiota is required to preserve its anti-inflammatory activity. Remarkably, the protective effect of phloroglucinol lasts partially at least 6 months. Single-cell transcriptomic analysis of bone marrow progenitors demonstrates the capacity of the metabolite to induce long-lasting innate immune training in hematopoietic lineages, at least partially through the participation of the receptor and transcription factor, aryl hydrocarbon receptor (AhR). Phloroglucinol induces alterations in metabolic and epigenetic pathways that are most prevalent in upstream progenitors as hallmarks of central trained immunity. These data identify phloroglucinol as a dietary-derived compound capable of inducing central trained immunity and modulating the response of the host to inflammatory insults., This work was supported by MCIN/AEI/10.13039/501100011033(PID2021-124328OB-100 to JA, AGL2017-86757-R and RYC-2013-13666 to LA, SAF2015-73549-JIN to HR, PID2020-117911RB-100 to AFT). MGA is funded by the DeutscheForschungsgemeinschaft (DFG, German researchFoundation) – SFB 1583/1 [Project number: 492620490] andSPP 2330 [Project number: 465341196]. Supported in part byFundación Jesús de Gangoiti and by fellowships from Getteccu(Geteccu-MSD to HR and LA, and Geteccu-FreseniusKabi to JA).CIC bioGUNE is the recipient of a Severo Ochoa Centro deExcelencia award [CEX2021-001136-S].JC was partly supported18 J. CASTELO ET AL. by a FEMS Research and Training Grant [1816] and an EMBOScientific Exchange Grant [9792]. APa and IS were supported bya predoctoral fellowship from the Basque Government. APe wassupported by a postdoctoral fellowship from the BasqueGovernment. DB [BES-2016-078437], SAA [PRE-2019-091720],APl [PRE2018-085772] and ESF [PRE2022-104669] were recipi-ents of MCIU FPI fellowships from MCIN/AEI/10.13039/501100011033. APC was a recipient of a fellowship from theUniversity of the Basque Country. NG held a predoctoral grantfrom the Scientific Foundation of the Spanish AssociationAgainst Cancer in Biscay [PRDVZ222452GUTI]. We thank theBasque Department of Industry, Tourism and Trade (Etortek andElkartek programs) and the Innovation Technology Departmentof the Bizkaia Province. This project has received funding fromthe European Union’s Horizon 2020 research and innovationprogramme under the Marie Skłodowska-Curie grant agreementNº 860325 to STP and JA., Peer reviewed